- Jim Goodwin, Washington University in St. Louis
- Read Time: 6 mins
We think this is the first report of the use of a neoantigen DNA vaccine in a human, and our monitoring confirms the vaccine was successful in prompting an immune response that targeted specific neoantigens in the patient's tumor